Study: Endometrial biomarkers in premenopausal women with obesity, reported by Dottino and colleagues in the American Journal of Obstetrics and Gynecology in 2021. 123
Published data: The cross-sectional cohort prospectively enrolled 97 women with BMI ≥30 and 33 with BMI ≤25, with timed endometrial biopsies and metabolic testing. In histologically normal endometrium, the obesity group had lower expression of progesterone receptor (P=.0027), retinaldehyde dehydrogenase 2 (P=.008), IGF-1 (P=.016), and survivin (P=.042). Several associations persisted after adjustment. Endometrial proliferation did not differ; a separately examined Lynch-syndrome cohort showed a different IGF-1 pattern. 23
Interpretation: These tissue findings challenge a simple assumption that obesity uniformly produces a locally estrogen-stimulated endometrium in premenopausal women. They do not show that obesity prevents cancer, validate a screening test, or demonstrate reduced cancer incidence. This was biomarker research, not a prevention-treatment trial. 23